Taddese Menassie bought XERS
November 2, 2026 · Form 4 insider transaction
Taddese Menassie bought 22,365 shares of Xeris Biopharma Holdings, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Acquired (buy-side)
Shares
22,365
Price
$0.00
Total value
N/A
InsiderTaddese Menassie
Role—
SecurityCommon Stock
Transaction codeA: Grant or award
Transaction dateNovember 2, 2026
Filing dateNovember 4, 2026
Shares owned after22,365
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued service on the Company's Board of Directors through such vesting date.